home / stock / qlgn / qlgn news

QLGN News and Press, Qualigen Therapeutics Inc. From 04/05/22

Stock Information
Company Name: Qualigen Therapeutics Inc.
Stock Symbol: QLGN
Market: NASDAQ
Website: qualigeninc.com
Menu
QLGN QLGN Quote QLGN Short QLGN News QLGN Articles QLGN Message Board
Get QLGN Alerts

News, Short Squeeze, Breakout and More Instantly...
QLGN - Qualigen Therapeutics climbs 3% on resuming worldwide distribution and commercial control over Fastpack

Qualigen Therapeutics (NASDAQ:QLGN) resumed worldwide distribution and commercial control of FastPack from previous marketing partner Sekisui Diagnostics from April 1, 2022. The sale of FastPack System diagnostic instruments and test kits have exceeded $120M since inception and have...
QLGN - Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack®

Company Prepared for Growth and Improved Profitability of its Diagnostics Business CARLSBAD, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences...

QLGN - Qualigen Therapeutics GAAP EPS of -$0.61, revenue of $5.65M

Qualigen Therapeutics press release (NASDAQ:QLGN): FY GAAP EPS of -$0.61. Revenue of $5.65M (+98.2% Y/Y). Shares -3.92% PM. For further details see: Qualigen Therapeutics GAAP EPS of -$0.61, revenue of $5.65M

QLGN - Qualigen Therapeutics, Inc. Reports Year-End 2021 Financial Results

CARLSBAD, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics, today ann...
QLGN - Qualigen contracts TD2 for preclinical development of QN-302

Qualigen Therapeutics (NASDAQ:QLGN +3.5%) selected contract research organization (CRO) Translational Drug Development (TD2) to lead the preclinical development of its lead drug candidate QN-302. Qualigen is initially investigating QN-302 for the potential treatment of pancreat...

QLGN - Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302

CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today ann...

QLGN - Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conference

Abstracts Review Positive In vivo Data an d the Potential Mechanism of Action for QN-302 in Pancreatic and Prostate Cancers CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company fo...
QLGN - Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS Program

CARLSBAD, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics, today ann...

QLGN - Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders

CARLSBAD, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation and diagnostics, today issues the following Letter ...

QLGN - Data from Qualigen Therapeutics' Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference

Posters to be Presented During the In-Person Conference Being Held April 8-13, 2022 in New Orleans CARLSBAD, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers...
Previous 10 Next 10